首页 › 基金 › Fundsmith LLP › ADMA
Fundsmith LLP 对 ADMA 的持仓历史
ADMA BIOLOGICS INC · 医疗保健
Fundsmith LLP 在 Q2 2026 的 13F 申报中披露持有 ADMA(ADMA BIOLOGICS INC)1,649,493 股,市值约 US$13.8M,约占其申报组合的 0.10%,在其申报持仓中市值排名第 39 位。 Fundsmith LLP 最近 3 个申报季度中有 3 个季度披露了 ADMA 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Fundsmith LLP 对 ADMA 的持仓演变
Fundsmith LLP 于 Q4 2025 首次披露 ADMA 持仓:2,102,054 股(约 US$38.3M)。 在 3 次申报中,Fundsmith LLP 0 次增持、1 次减持、1 次保持不变。 最近一期申报(Q2 2026)显示持股 1,649,493 股、市值约 US$13.8M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 2.10M | $38.34M | 新进 |
| Q1 2026 | 1.65M | $14.86M | 减持 |
| Q2 2026 | 1.65M | $13.81M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ADMA 与 13F 数据
ADMA(ADMA BIOLOGICS INC)属于医疗保健行业。我们追踪的基金中还有 18 只申报持有 ADMA,申报仓位最大的包括:Rubric Capital Management LP (US$78.2M), B Group, Inc. (US$27.3M), Duquesne Family Office LLC (US$23.3M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ADMA 的基金
- Rubric Capital Management LP 9.34M 股 · $78.17M · Q2 2026
- B Group, Inc. 3.26M 股 · $27.31M · Q2 2026
- Duquesne Family Office LLC 2.78M 股 · $23.30M · Q2 2026
更多关于 Fundsmith LLP
常见问题
How long has Fundsmith LLP held ADMA?
Fundsmith LLP has disclosed ADMA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Fundsmith LLP's current position in ADMA?
As of Q2 2026, Fundsmith LLP holds 1.65M shares of ADMA (ADMA BIOLOGICS INC), valued at $13.81M, representing 0.10% of its reported portfolio and ranking #39.
Has Fundsmith LLP been buying or selling ADMA?
In the latest 13F filing (Q2 2026), Fundsmith LLP held unchanged its position in ADMA.
Which other funds hold ADMA?
Other major institutional holders of ADMA include Rubric Capital Management LP, B Group, Inc., Duquesne Family Office LLC, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.